HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

The adenosine A2A receptor antagonist, istradefylline enhances the anti-parkinsonian activity of low doses of dopamine agonists in MPTP-treated common marmosets.

Abstract
The adenosine A2A receptor antagonist, istradefylline, enhances anti-parkinsonian activity in patients with advanced Parkinson׳s disease (PD) already treated with combinations of L-DOPA and dopamine agonist drugs but who are still exhibiting prolonged 'OFF' periods. In contrast, the effects of istradefylline on motor function when administered in combination with low dose dopamine agonist therapy in early PD are unknown. We now investigate whether istradefylline administered with a threshold dose of either the non-ergot dopamine agonist, ropinirole or the ergot dopamine agonist, pergolide enhances anti-parkinsonian activity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated common marmoset. Both ropinirole (0.01-0.1mg/kg p.o.) and pergolide (0.003-0.1mg/kg p.o.) administered alone produced dose dependent increases in locomotor activity, a reduction in motor disability. Threshold doses of ropinirole (0.025-0.075mg/kg p.o.) and pergolide (0.01-0.075mg/kg p.o.) were then selected that in individual animals caused a small but non-significant anti-parkinsonian effect. Administration of istradefylline (10mg/kg p.o.) alone resulted in a decrease in motor disability and increase in 'ON' time but dyskinesia was not observed. Combined administration of pergolide or ropinirole with istradefylline resulted in an increase in the reversal of motor disability and increase in 'ON' time compared to that produced by either treatment alone but dyskinesia was still not observed. These results show that istradefylline is effective in improving motor function when combined with low dose dopamine agonist treatment. In early PD, this may avoid dose escalation or allow a reduction in dopamine agonist dosage without a loss of efficacy and prevent dopaminergic side-effects from becoming treatment limiting.
AuthorsShin-ichi Uchida, Kazuhiro Soshiroda, Eri Okita, Mika Kawai-Uchida, Akihisa Mori, Peter Jenner, Tomoyuki Kanda
JournalEuropean journal of pharmacology (Eur J Pharmacol) Vol. 747 Pg. 160-5 (Jan 15 2015) ISSN: 1879-0712 [Electronic] Netherlands
PMID25499739 (Publication Type: Journal Article)
CopyrightCopyright © 2014 Elsevier B.V. All rights reserved.
Chemical References
  • Adenosine A2 Receptor Antagonists
  • Antiparkinson Agents
  • Dopamine Agonists
  • Indoles
  • Purines
  • Receptor, Adenosine A2A
  • ropinirole
  • Pergolide
  • istradefylline
  • Levodopa
  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Topics
  • 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (adverse effects)
  • Adenosine A2 Receptor Antagonists (pharmacology)
  • Animals
  • Antiparkinson Agents (pharmacology)
  • Callithrix
  • Dopamine Agonists (pharmacology)
  • Dose-Response Relationship, Drug
  • Drug Synergism
  • Female
  • Indoles (pharmacology)
  • Levodopa (pharmacology)
  • Male
  • Motor Activity (drug effects)
  • Pergolide (pharmacology)
  • Purines (pharmacology)
  • Receptor, Adenosine A2A (metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: